Last updated: June 11, 2026
PLATINOL (cisplatin) Suppliers: Which Companies Manufacture, Supply, and Distribute the Drug?
Executive summary: PLATINOL is the brand name for cisplatin (a platinum-based chemotherapy). The market is supplied through a mix of originator-brand channels, generic manufacturers, and API sources. Supplier identification for “PLATINOL” specifically depends on the country, the strength/formulation (typically IV infusion concentrate), and the marketing authorization holder in that jurisdiction.
What companies supply PLATINOL (cisplatin) injections by market?
Featured snippet answer: PLATINOL supply is typically handled by marketing authorization holders and distributors in each country, while production is performed by manufacturers of cisplatin sterile injection under GMP and packaged for local labeling.
Key supplier categories
- Brand/marketing authorization holder (MAH): Owns the labeled product and coordinates supply and distribution to wholesalers and hospitals.
- Contract manufacturers: Produce sterile cisplatin concentrate for IV under contract for the MAH.
- Generic manufacturers: Sell equivalent cisplatin injections under local marketing authorizations.
- API manufacturers: Produce cisplatin active pharmaceutical ingredient for finished-dose manufacturers (FDs).
How to read “PLATINOL supplier” searches
- If “PLATINOL” appears in regulatory databases or tender documents, supplier typically means the labeled product MAH/distributor.
- If “cisplatin injection supplier” appears, it usually means finished-dose manufacturers or tenderable product sources.
Which manufacturers make cisplatin injection (the underlying API drug product) used as PLATINOL?
Featured snippet answer: Cisplatin injections are made by sterile injectables manufacturers that handle platinum compounds under GMP, typically producing:
- cisplatin concentrate for dilution in an IV solution, and
- cisplatin sterile injection in single-dose vials/ampoules depending on the market.
Common dosage forms relevant to PLATINOL
- IV infusion concentrate (most common for hospital oncology use)
- Sterile solution (market-dependent)
- Single-dose vials for aseptic preparation
Technical supply constraints that shape the supplier landscape
- GMP aseptic manufacturing for hazardous chemotherapies
- Containment and cleaning validation for platinum residue control
- Stability and packaging compatibility for aqueous cisplatin formulations
Who supplies cisplatin API that feeds PLATINOL and other brands?
Featured snippet answer: Cisplatin API supply comes from specialty API plants producing platinum coordination compounds. API sources feed multiple finished-dose manufacturers that then supply products labeled as PLATINOL or as generics, depending on jurisdiction.
API supply chain roles
- API producer: manufactures and supplies cisplatin bulk substance
- Finished dose manufacturer: formulates and packages under local regulatory requirements
- Secondary packer/distributor: may repackage or label for local markets where allowed
What is the Orange Book status of PLATINOL (cisplatin)?
Featured snippet answer: In the US, cisplatin is an established drug with multiple approved presentations, with Orange Book listings varying by label strength and dosage form. “PLATINOL” may not be the same listing name as generic cisplatin products in every presentation; US status is tied to the specific NDC/strength.
What to look for in Orange Book records
- Active ingredient: cisplatin
- Dosage form: injection (often concentrate)
- Applicant/labeler: the company holding the NDA/ANDA for that presentation
- Patent/subpatent listings: may cover formulation, use, or manufacturing aspects for some presentations
Which company holds the PLATINOL marketing authorization (MAH) in a specific country?
Featured snippet answer: The PLATINOL marketing authorization holder (and local distributor) is the first-party supplier for tendering and hospital procurement in that country.
Why MAH differs from manufacturing
- MAH can outsource manufacturing to a contract site
- Distributor can differ from MAH for logistics
What generic entry risks exist for cisplatin brands like PLATINOL?
Featured snippet answer: For established oncology injectables like cisplatin, generic entry risk is usually driven by the continued availability of affordable sterile supply and the regulatory status of specific presentations, rather than by broad “PLATINOL-specific” exclusivity.
Drivers of supply interruption and competitive substitution
- Plant outages at sterile injectables facilities
- Raw material availability for platinum APIs
- Regulatory inspection outcomes
- Pricing pressure leading to reduced supplier diversity
How does PLATINOL supply compare with other cisplatin injection brands and generics?
Featured snippet answer: Competitive supply is usually segmented by presentation (strength, container type) and by local labeling. In many markets, hospitals can substitute between branded cisplatin and generics with equivalent dosing if the formulation is approved for that jurisdiction.
Procurement reality
- Oncology formularies often specify cisplatin injection rather than a single brand name.
- Substitution policies depend on local regulatory and hospital procurement rules.
Which regions have the most supplier options for PLATINOL (cisplatin) injections?
Featured snippet answer: Supplier options typically increase in regions with a mature generics/sterile injectables base, but market-specific availability is affected by:
- local tender structures,
- distribution networks,
- and sterile manufacturing capacity for hazardous drugs.
Regional supplier patterns
- US/EU: multiple equivalent cisplatin products, frequent tender-based substitution
- Emerging markets: fewer sterile supply chains, higher risk of stockouts during capacity strain
Key Takeaways
- “PLATINOL” is a brand name for cisplatin, and “supplier” in practice usually refers to the local marketing authorization holder/distributor plus the underlying sterile injectables manufacturer.
- Supplier lists are jurisdiction-specific and presentation-specific (strength, vial type, concentrate vs ready-to-use).
- API supply for cisplatin comes from specialty platinum API producers feeding multiple finished-dose manufacturers.
FAQs
-
What does “PLATINOL supplier” mean in hospital tenders?
It usually refers to the tenderable labeled product supplier (MAH/labeler and distribution chain) rather than the API producer.
-
Can hospitals substitute cisplatin generics for PLATINOL?
Often yes, substitution depends on formulary rules and approved presentation equivalence (strength, concentrate vs solution).
-
Why do cisplatin supply shortages occur even with multiple product brands?
The bottleneck is frequently sterile manufacturing capacity, containment/validation constraints, and API supply.
-
Do cisplatin patents meaningfully limit competition for PLATINOL?
For established cisplatin injection, competition is usually driven by regulatory approval status by presentation and manufacturing capacity, not brand-wide exclusivity.
-
How are cisplatin injection suppliers qualified for procurement?
Buyers typically require GMP compliance, documented supply reliability, batch traceability, and regulatory standing for the specific NDC/marketing authorization.
References
No sources were provided in the prompt, and I did not cite any external material.
